



MotherToBaby

Medicamentos y Más Durante el Embarazo y la Lactancia
Pregunte a los Expertos

Hoja Informativa

por la **Organización de Especialistas en Información de Teratología (OTIS)**.
Para más información de nuestros servicios o para encontrar servicios en su área,
llame al **(866) 626-6847**. Visítenos en la red en **www.MotherToBaby.org**.
¡Encuéntrenos! Facebook.com/MotherToBaby o @MotherToBaby en Twitter.

Certolizumab Pegol (Cimzia®)

Selected References:

- Mariette X, et al. 2017. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study., *Ann Rheum Dis*; 0:1–6. doi:10.1136/annrheumdis-2017-212196
- Clowse, ME, et al. 2018. Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from a Pharmacovigilance Safety Database. *Arthritis Rheumatol*. Accepted Author Manuscript. doi:10.1002/art.40508
- Clowse MEB, et al. 2017. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. *Ann Rheum Dis*; 76:1890–1896.
- Cimzia Prescribing Information. Available online at https://www.cimzia.com/sites/default/files/docs/CIMZIA_Current_COL_03-2018_effective_21_March_2018.pdf Accessed 16 April 2018.
- Förger F, et al. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients. *Joint Bone Spine*. 83:341–343.
- Habal FM and Huang VW. 2012. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. *Aliment Pharmacol Ther* 35(5):501-15.
- Khan N, et al. 2014. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. *Expert Opin Drug Saf*; 13(12):1699-708.
- Mahadevan U, et al. 2011. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: pregnancy and pediatrics. *Am J Gastroenterol*. 106(2):214-23
- Mahadevan U, et al. 2012. PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. *Gastroenterology*. 142(Suppl 1):S149. Abstract 865.
- Mahadevan, U., et al. 2017. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients with Inflammatory Bowel Disease. *Gastroenterology* 152(2):451-462.e452.
- Oussalah A, et al. 2009. Certolizumab use in pregnancy. *Gut*. 58(4):608.
- Wakefield I, et al. 2011. The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNF alpha PEGylated Fab' monoclonal antibody. *Toxicol Sci* 122(1):170-6.
- Weber-Schoendorfer C; network of French pharmacovigilance centres, et al. 2015. Pregnancy outcome after TNF-? inhibitor therapy during the first trimester: a prospective multicentre cohort study. *Br J Clin Pharmacol*; 80(4):727-39.
- Wolf D and Mahadevan U. 2010. Certolizumab use in pregnancy: low levels detected in cord blood. *Arthritis Rheum* [abstract] 62Suppl10:718.

abril, 2018